Syncona Investment Management Limited (SIML) is a leading life science investor and company creator, founded by the Wellcome Trust to build and scale transformational healthcare companies from world class science. Since inception in 2012, we have built 27 companies, deployed over £1.4bn, and generated more than £1bn of exit proceeds, delivering a 51% gross IRR on realised investments.

Our thesis is that the most attractive returns in healthcare are created by advancing truly differentiated science to late stage inflection points, where value is most clearly realised. We take a hands on, high ownership approach - forming companies around pioneering discoveries, creating and backing exceptional management teams, and actively driving assets through development to maximise value.

Our private fund seeks to build on this proven company creation model, combining privileged access to breakthrough innovation - anchored in the UK’s globally leading academic ecosystem - with a capital structure designed for and aligned with biotech timelines.

SIML offers investors differentiated access to late stage life science value creation and out returns, underpinned by an established platform, deep scientific expertise, and a track record of building global leaders at the intersection of science, capital and patient impact.